Can you take Flibanserin with Sulfinpyrazone?
1 drug interaction and 15 additional warnings found for the following 2 drugs:
- flibanserin
- sulfinpyrazone
Drug interactions
Moderate drug interactions
Moderate:
sulfinpyrazone flibanserin
Applies to: sulfinpyrazone and flibanserin
Sulfinpyrazone may reduce the blood levels of flibanserin, which may make the medication less effective in treating your condition.
Contact your doctor if your symptoms worsen or your condition changes. Your doctor may be able to prescribe alternatives that do not interact, or you may need a dose adjustment or more frequent monitoring to safely use both medications.
It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Food/lifestyle interactions
Major food/lifestyle interactions
Major:
flibanserin Food/Lifestyle
Applies to: flibanserin
Do not use alcohol too close to the dosing time of flibanserin. Doing so can cause excessive drowsiness and decreases in blood pressure, which may lead to:
- dizziness
- lightheadedness
- fainting
- accidental injury
What to do: Take flibanserin at bedtime to minimize the risk of these effects. It is recommended that you stop drinking alcohol at least two hours before taking flibanserin; otherwise, you should just skip the flibanserin dose that evening. Alcohol should not be consumed until at least the morning after taking flibanserin at bedtime.
Because grapefruit juice can significantly increase the blood levels of flibanserin, you should also avoid the consumption of grapefruit and grapefruit juice during treatment.
Talk to your healthcare provider if you have any questions or concerns. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Disease interactions
14 potential interactions Applies to: 14 conditions, including Gastritis/Duodenitis, Diarrhea, Hypotension, Anemia, and Peptic Ulcer.
Alcoholism
Major:
flibanserin
Flibanserin has a major potential interaction with Alcoholism.
The use of flibanserin is contraindicated along with the ingestion of alcohol, as it increases the risk of hypotension and syncope. It is important to assess the likelihood of the patient abstaining from alcohol, taking into account the current and past drinking behavior.
Anemia
Major:
sulfinpyrazone
Sulfinpyrazone has a major potential interaction with Anemia.
The use of sulfinpyrazone is contraindicated in patients with a current or past history of blood dyscrasias. Anemia, leukopenia, agranulocytosis, thrombocytopenia, and aplastic anemia have been reported rarely with sulfinpyrazone use. Phenylbutazone, a structurally related agent, has been associated frequently with bone marrow suppression, as well as an increased risk of leukemia. Periodic blood counts are recommended when sulfinpyrazone or other pyrazole compounds are used.
Bone Marrow Depression/Low Blood Counts
Major:
sulfinpyrazone
Sulfinpyrazone has a major potential interaction with Bone Marrow Depression/Low Blood Counts.
The use of sulfinpyrazone is contraindicated in patients with a current or past history of blood dyscrasias. Anemia, leukopenia, agranulocytosis, thrombocytopenia, and aplastic anemia have been reported rarely with sulfinpyrazone use. Phenylbutazone, a structurally related agent, has been associated frequently with bone marrow suppression, as well as an increased risk of leukemia. Periodic blood counts are recommended when sulfinpyrazone or other pyrazole compounds are used.
Dehydration
Moderate:
sulfinpyrazone
Sulfinpyrazone has a moderate potential interaction with Dehydration.
Adequate hydration is necessary during therapy with sulfinpyrazone to prevent the renal precipitation of urates. Patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk and should be encouraged to consume additional amounts of liquid or given intravenous fluid. In general, fluid intake sufficient to yield a daily urinary output of at least 2 liters is recommended. Maintenance of a slightly alkaline or neutral urine is also desirable.
Diarrhea
Moderate:
sulfinpyrazone
Sulfinpyrazone has a moderate potential interaction with Diarrhea.
Adequate hydration is necessary during therapy with sulfinpyrazone to prevent the renal precipitation of urates. Patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk and should be encouraged to consume additional amounts of liquid or given intravenous fluid. In general, fluid intake sufficient to yield a daily urinary output of at least 2 liters is recommended. Maintenance of a slightly alkaline or neutral urine is also desirable.
Gastritis/Duodenitis
Major:
sulfinpyrazone
Sulfinpyrazone has a major potential interaction with Gastritis/Duodenitis.
The use of sulfinpyrazone is contraindicated in patients with active peptic ulcer disease or symptoms of gastrointestinal inflammation or ulceration. Sulfinpyrazone may commonly cause upper gastrointestinal irritation. It may also aggravate or reactivate peptic ulcer. Therapy with sulfinpyrazone may be administered cautiously in patients with a history of healed peptic ulcer. Taking the medication with food, milk, or antacids may lessen GI adverse effects.
History, Peptic Ulcer
Major:
sulfinpyrazone
Sulfinpyrazone has a major potential interaction with History, Peptic Ulcer.
The use of sulfinpyrazone is contraindicated in patients with active peptic ulcer disease or symptoms of gastrointestinal inflammation or ulceration. Sulfinpyrazone may commonly cause upper gastrointestinal irritation. It may also aggravate or reactivate peptic ulcer. Therapy with sulfinpyrazone may be administered cautiously in patients with a history of healed peptic ulcer. Taking the medication with food, milk, or antacids may lessen GI adverse effects.
History of Blood Dyscrasias
Major:
sulfinpyrazone
Sulfinpyrazone has a major potential interaction with History of Blood Dyscrasias.
The use of sulfinpyrazone is contraindicated in patients with a current or past history of blood dyscrasias. Anemia, leukopenia, agranulocytosis, thrombocytopenia, and aplastic anemia have been reported rarely with sulfinpyrazone use. Phenylbutazone, a structurally related agent, has been associated frequently with bone marrow suppression, as well as an increased risk of leukemia. Periodic blood counts are recommended when sulfinpyrazone or other pyrazole compounds are used.
Hypotension
Major:
flibanserin
Flibanserin has a major potential interaction with Hypotension.
The use of flibanserin can cause hypotension and syncope. The benefits and risks of therapy should be considered in patients with preexisting conditions that predispose to hypotension. Flibanserin should be used with caution in these patients.
Liver Disease
Major:
flibanserin
Flibanserin has a major potential interaction with Liver Disease.
Flibanserin may accumulate in patients with hepatic impairment. Therapy with flibanserin is contraindicated in patients with compromised hepatic function.
Peptic Ulcer
Major:
sulfinpyrazone
Sulfinpyrazone has a major potential interaction with Peptic Ulcer.
The use of sulfinpyrazone is contraindicated in patients with active peptic ulcer disease or symptoms of gastrointestinal inflammation or ulceration. Sulfinpyrazone may commonly cause upper gastrointestinal irritation. It may also aggravate or reactivate peptic ulcer. Therapy with sulfinpyrazone may be administered cautiously in patients with a history of healed peptic ulcer. Taking the medication with food, milk, or antacids may lessen GI adverse effects.
Renal Dysfunction
Moderate:
sulfinpyrazone
Sulfinpyrazone has a moderate potential interaction with Renal Dysfunction.
Renal failure has occasionally been reported with the use of sulfinpyrazone. Therapy with sulfinpyrazone should be administered cautiously in patients with significant renal impairment. Adequate hydration and periodic monitoring of renal function are recommended.
Syncope
Major:
flibanserin
Flibanserin has a major potential interaction with Syncope.
The use of flibanserin can cause hypotension and syncope. The benefits and risks of therapy should be considered in patients with preexisting conditions that predispose to hypotension. Flibanserin should be used with caution in these patients.
Vomiting
Moderate:
sulfinpyrazone
Sulfinpyrazone has a moderate potential interaction with Vomiting.
Adequate hydration is necessary during therapy with sulfinpyrazone to prevent the renal precipitation of urates. Patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk and should be encouraged to consume additional amounts of liquid or given intravenous fluid. In general, fluid intake sufficient to yield a daily urinary output of at least 2 liters is recommended. Maintenance of a slightly alkaline or neutral urine is also desirable.
Report options
More resources
flibanserin
A total of 517 drugs are known to interact with flibanserin.
- Flibanserin is in the drug class miscellaneous central nervous system agents.
- Flibanserin is used to treat Hypoactive Sexual Desire Disorder.
sulfinpyrazone
A total of 402 drugs are known to interact with sulfinpyrazone.
- Sulfinpyrazone is in the drug class antigout agents.
- Sulfinpyrazone is used to treat the following conditions:
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.